Reducing the risk of major elective non-cardiac surgery: Is there a role for levosimendan in the preoperative optimization of cardiac function?

Current Drug Targets

Volumn 10, Issue 9, 2009, Pages 863-871

  Morelli, A ^a   Ertmer, C ^b   Pietropaoli, P ^a   Westphal, M ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cardioprotection; Heart failure; Levosimendan; Non cardiac surgery; Perioperative optimization

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; LEVOSIMENDAN; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; NORADRENALIN; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR;

ADVERSE OUTCOME; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ELECTIVE SURGERY; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART PERFORMANCE; HEART PROTECTION; HEART SURGERY; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INOTROPISM; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; MICROCIRCULATION; PREOPERATIVE TREATMENT; PROTEIN INDUCTION; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SURGICAL MORTALITY; SURGICAL RISK; SYSTEMIC CIRCULATION; VASODILATATION;

HEART FAILURE; HUMANS; HYDRAZONES; PREOPERATIVE CARE; PYRIDAZINES; RISK ASSESSMENT; SURGICAL PROCEDURES, ELECTIVE; VASODILATOR AGENTS;

EID: 70450171316     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789108819     Document Type: Review

References (111)

1. Toufektzian L, Theodorou D, Larentzakis A, Misthos P, Katsaragakis S. Optimization of cardiac performance in chronic heart failure patients undergoing elective non-cardiac surgery. Curr Anaesth Crit Care 2007; 18: 50-57 (Pubitemid 46994595)
2. Feringa HH, Bax JJ, Poldermans D. Perioperative medical management of ischemic heart disease in patients undergoing noncardiac surgery. Curr Opin Anaesthesiol 2007; 20: 254-260 (Pubitemid 46705397)
3. Toller WG, Metzler H. Acute perioperative heart failure. Curr Opin Anaesth 2005; 18: 129-135
4. Mangano DT. Adverse outcomes after surgery in the year 2001 - a continuing odyssey. Anesthesiology 1998; 88: 561-564
5. Mangano DT, Goldman L. Preoperative assessment of patients with known or suspected coronary disease. N Engl J Med 1995; 333: 1750-1756 (Pubitemid 26007128)
6. Bai J, Hashimoto J, Nakahara T, Suzuki T, Kubo A. Influence of ageing on perioperative cardiac risk in noncardiac surgery. Age Ageing 2007; 36: 68-72 . (Pubitemid 47072037)
7. The Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative. Eur J Heart Fail 1999; 1: 139-144
8. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-1402 . (Pubitemid 35239711)
9. Hernandez AF, Whellan DJ, Stroud S, Sun JL, O'Connor CM, Jollis JG. Outcomes in heart failure patients after major noncardiac surgery. J Am Coll Cardiol 2004; 44: 1446-1453 (Pubitemid 39303947)
10. Mangano DT, Browner WS, Hollenberg M, London MJ, Tubau JF, Tateo IM. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. N Engl J Med 1990; 323: 1781-1788
11. Soeding PF, Royse CF, Wright CE, Royse AG, Angus JA. Inoprotection: The perioperative role of levosimendan. Anaesth Intens Care 2007; 35: 845-862.
12. Larsen SF, Olesen KH, Jacobsen E, Nielsen H, Nielsen AL, Pietersen A, et al. Prediction of cardiac risk in non-cardiac surgery. Eur Heart J 1987; 8: 179-185 (Pubitemid 17034171)
13. Dawood MM, Gupta DK, Southern J, Walia A, Atkinson JB, Eagle KA. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol 1996; 57: 37-44. (Pubitemid 26388825)
14. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006; 104: 556-569
15. Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C. Levosimendan: Beyond its simple inotropic effect in heart failure. Pharmacol Ther 2007; 114: 184-197 (Pubitemid 46561532)
16. Katsaragakis S, Kapralou A, Markogiannakis H, Kofinas G, Theodoraki EM, Larentzakis A, et al. Preoperative levosimendan in heart failure patients undergoing noncardiac surgery. Neth J Med 2008; 66: 154-159 (Pubitemid 351593774)
17. Ponschab M, Hochmair N, Ghazwinian N, Mueller T, Plöchl W. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair. Eur J Anaesthesiol 2008; 25: 627-633 (Pubitemid 351914991)
18. Archan S, Toller WG. Levosimendan: current status and future prospects. Curr Opin Anaesthesiol 2008; 21: 78-84.
19. Raja SG, Rayen BS. Levosimendan in cardiac surgery: current best available evidence. Ann Thorac Surg 2006; 81: 1536-1546 .
20. Zangrillo A, Biondi-Zoccai G, Mizzi A, Bruno G, Bignami E, Gerli C, et al. Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth 2009; Feb 11 [Epub ahead of print].
21. Barisin S, Husedzinovic I, Sonicki Z, Bradic N, Barisin A, Tonkovic D. Levosimendan in off-pump coronary artery bypass. J Cardiovasc Pharmacol 2004; 44: 703-708
22. Nijhawan N, Nikolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass. J Cardiovasc Pharmacol 1999; 34: 219-228
23. Sorsa T, Pollesello P, Rosevear PR, Drakenberg T, Kilpeläinen I. Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization. Eur J Pharmacol 2004; 486: 1-8. (Pubitemid 38130154)
24. Antila S, Kivikko M, Lehtonen L, Eha J, Heikkilä A, Pohjanjousi P, et al. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol 2004; 57: 412-415 (Pubitemid 38519645)
25. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107: 81-86 (Pubitemid 36070937)
26. Lilleberg J, Laine M, Palkama T, Kivikko, M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2007; 9: 75-82. (Pubitemid 46074480)
27. Jonsson, EN, Antila S, McFadyen L, Lehtonen L, Karlsson MO. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol 2003; 55: 544-551. (Pubitemid 36783195)
28. Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of New Agents for Acute Heart Failure Syndromes. Am J Cardiol 2005; 96: 68G-73G. (Pubitemid 41338076)
29. Pinto BB, Rheberg S, Ertmer C, Westphal M. Role of levosimendan in sepsis and septic shock. Curr Opin Anaesthiol 2008; 21: 168-177 .
30. Mebazaa A, Cohen-Solal A, Kleber FX. Levosimendan reduces mortality when compared with dobutamine in patients receiving beta blockers: The SURVIVE study. Intens Care Med 2007; 33: S92.
31. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002; .40: 465-471. (Pubitemid 35153452)
32. ++) in guinea pig isolated ventricular myocytes. Eur J Pharmacol 1997; 339: 97-100.
33. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995; 27: 1859-1866
34. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995; 25: 794-801.
35. McGough MF, Pagel PS, Lowe D, Hettrick DA, Kersten JR, Warltier DC. Effects of levosimendan on left ventricular function: correlation with plasma concentrations in conscious dogs. J Cardiothorac Vasc Anesth 1997; 11: 49-53. (Pubitemid 27114208)
36. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43: 2177-2182 (Pubitemid 38757582)
37. Szilagyi S, Pollesello P, Levijoki J, Haikala H, Bak I, Tosaki A, et al. Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone. J Cardiovasc Pharmacol 2005; 46: 369-376. (Pubitemid 41262841)
38. ++ current via phosphodiesterase- 3 inhibition in human cardiac myocytes. Eur J Pharmacol 2002; 435: 27-33.
39. Shahid M, Nicholson CD. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram. Naunyn Schmiedebergs Arch Pharmacol 1990; 342: 698-705 .
40. Verde I, Vandecasteele G, Lezoualc'h F, Fischmeister R. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes. Br J Pharmacol 1999; 127: 65-74. (Pubitemid 29213233)
41. Cone J, Wang S, Tandon N, Fong M, Sun B, Sakurai K, et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 1999; 34: 497-504. (Pubitemid 29446916)
42. Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 2004; 486: 67-74. (Pubitemid 38130162)
43. Shoemaker WC, Appel PL, Kram HB. Role of oxygen debt in the development of organ failure sepsis, and death in high-risk surgical patients. Chest 1992; 102: 208-215
44. Older R, Smith R, Courtney P, Hone R. Preoperative evaluation of cardiac failure and ischemia in elderly patients by cardiopulmonary exercise testing. Chest 1993; 104: 701-704 (Pubitemid 23268935)
45. Donati A, Loggi S, Preiser JC, Orsetti G, Münch C, Gabbanelli V, et al. Goal-directed intraoperative therapy reduces morbidity and length of hospital stay in high-risk surgical patients. Chest 2007; 132: 1817-1824
46. Takala J, Meier-Hellmann A, Eddleston J, Hulstaert P, Sramek V. Effect of dopexamine on outcome after major abdominal surgery: a prospective, randomized, controlled multicenter study. European Multicenter Study Group on Dopexamine in Major Abdominal Surgery.Crit Care Med 2000; 28: 3417-3423 (Pubitemid 30792361)
47. Wilson J, Woods I, Fawcett J, Whall R, Dibb W, Morris C, et al. Reducing the risk of major elective surgery: randomised controlled trial of preoperative optimisation of oxygen delivery. BMJ 1999; 318: 1099-1103 (Pubitemid 29192147)
48. Konttinen N, Rosenberg PH. Outcome after anaesthesia and emergency surgery in patients over 100 years old. Acta Anaesthesiol Scan 2006; 50: 283-289
49. Flancbaum L, Ziegler DW, Choban PS. Preoperative intensive care unit admission and hemodynamic monitoring in patients scheduled for major elective noncardiac surgery: a retrospective review of 95 patients. J Cardiothorac Vasc Anesth 1998; 12: 3-9. (Pubitemid 28128416)
50. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330: 1717-1722 (Pubitemid 24171030)
51. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46: 57-64.
52. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005; 111: 1504-1509 (Pubitemid 40470645)
53. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005; 353: 349-361 (Pubitemid 41132339)
54. Follath F, Cleland JGF, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002; 360: 196-202. (Pubitemid 34804646)
55. Leppikangas H, Tenhunen JJ, Lindgren L, Salenius JP, Ruokonen E. Effects of levosimendan on indocyanine green plasma disappearance rate and the gastric mucosal-arterial pCO2 gradient in abdominal aortic aneurysm surgery. Acta Anaesthesiol Scand 2008; 52: 785-792 (Pubitemid 351829483)
56. Pataricza J, Krassoi I, Hohn J, Kun A, Papp JG. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003; 17: 115-121 (Pubitemid 37174684)
57. Guarracino F, Cariello C, Danella A, Doroni L, Lapolla F, Stefani M, et al. Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy. Acta Anaesthesiol Scand 2007; 51: 1217-1224 (Pubitemid 47389692)
58. Erdei N, Papp Z, Pollesello P, Edes I, Bagi Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K (ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol 2006; 148; 696-702. (Pubitemid 43993060)
59. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001; 37: 367-374 (Pubitemid 32240418)
60. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005; 111: 1504-1509 (Pubitemid 40470645)
61. Gruhn N, Nielsen Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium sensitizing properties. J Cardiovasc Pharmacol 1998; 31: 741-749 (Pubitemid 28217595)
62. DeWitt BJ, Ibrahim IN, Bayer E, Fields AM, Richards TA, Banister RE, et al. An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 2002; 94: 1427-1433 (Pubitemid 34556617)
63. Pagel PS, Hettrick DA, Warltier DC. Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventriculararterial coupling and mechanical efficiency. Basic Res Cardiol 1996; 91: 296-307.
64. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000; 102: 2222-2227 (Pubitemid 30808010)
65. Hohn J, Pataricza J, Petri A, Toth GK, Balogh A, Varro A, et al. Levosimendan interacts with potassium channel blockers in human saphenous veins. Basic Clin Pharmacol Toxicol 2004; 94: 271-273 (Pubitemid 38954893)
66. Elzinga G, Westerhof N. Matching between ventricle and arterial load. Circ Res 1991; 68: 1495-1500
67. Asanoi H, Kameyama T, Ishizaka S, Miyagi K, Sasayama S. Ventriculoarterial coupling during exercise in normal human subjects. Int J Cardiol 1992; 36: 177-186
68. Starling MR. Left ventricular-arterial coupling relations in the normal human heart. Am Heart J 1993; 125: 1659-1666
69. Sasayama S, Asanoi H. Coupling between the heart and arterial system in heart failure. Am J Med 1991; 90: 14-8S .
70. Asanoi H, Sasayama S, Kameyama T. Ventriculoarterial coupling in normal and failing heart in humans. Circ Res 1989; 65: 483-493 (Pubitemid 19194635)
71. Guarracino F, Tritapepe L, Morelli A. Letter by Guarracino et al. Regarding article, "direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of forcefrequency and relaxation-frequency relationships" Circulation 2007; 116: e346.
72. Mythen MG, Webb AR. Intra-operative gut mucosal hypoperfusion is assosiated with increased post-operative complications and cost. Intens Care Med 1994; 20: 99-104.
73. Nakatsuka M. Assessment of gut mucosal perfusion and colonic tissue blood flow during abdominal aortic surgery with gastric tonometry and laser doppler flowmetry. Vasc Endovasc Surg 2002; 36: 193-198 (Pubitemid 35278395)
74. Bohlen HG: Intestinal tissue PO2 and microvascular response during glucose exposure. Am J Physiol 1980; 238: H164-71.
75. Uusaro A, Ruokonen E, Takala J. Gastric mucosal ph does not reflect changes in splanchnic blood flow after cardiac surgery. Br J Anaest 1995; 74: 149-154
76. Tenhunen JJ, Martikainen TJ, Uusaro A, Ruokonen E. Dopexamine reverses colonic but not gastric mucosal perfusion defects lethal endotoxin shock. Br J Anaesth 2003; 91: 878-885 (Pubitemid 37508833)
77. Schwarte LA, Picker O, Bornstein SR, Fournell A, Scheeren TW. Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs. Crit Care Med 2005; 33: 135-142 (Pubitemid 40116548)
78. Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol 1996; 119: 609-615
79. Dubin A, Murias G, Sottile JP, Pozo MO, Barán M, Edul VS, et al. Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study. Intens Care Med 2007; 33: 485-494 (Pubitemid 46333847)
80. Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intens Care Med 2005; 31: 638-644 (Pubitemid 40684980)
81. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006; 47: 1-8.
82. Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007; 9: 872-878 (Pubitemid 47332311)
83. Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 2007; 21: 431-435 (Pubitemid 350231513)
84. Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail 2007; 13: 417-421 (Pubitemid 47176926)
85. Morelli A, Etmer C, Rehberg S, Orecchioni A, Cannuovacciuolo N, Bollen Pinto B, et al. Effects of levosimendan on renal function in septic shock: a case-control study. Crit Care 2009; 13(Suppl 1): P170 (13 March 2009) .
86. Fries M, Ince C, Rossaint R, Bleilevens C, Bickenbach J, Rex S, et al. Levosimendan but not norepinephrine improves microvascular oxygenation during experimental septic shock. Crit Care Med 2008; 36: 1886-1891
87. Morelli A Donati A, Ertmer C, Rehberg S, Bollen Pinto B, Orecchioni A, et al. Effects of levosimendan and invale nitric oxide on microcirculation in septic shock. Crit Care 2009; 13(Suppl 1): P169 (13 March 2009) .
88. Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs 2008; 17: 1143-1150
89. Roumen RM, Hendriks T, van der Ven-Jongekrijg J, Nieuwenhuijzen GA, Sauerwein RW, van der Meer JW, et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993; 218: 769-776
90. Seekamp A, Jochum M, Ziegler M, van Griensven M, Martin M, Regel G. Cytokines and adhesion molecules in elective and accidental trauma-related ischemia/reperfusion. J Trauma 1998; 44: 874-882 (Pubitemid 28233037)
91. Grossini E, Molinari C, Caimmi PP, Uberti F, Vacca G. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel. Br J Pharmacol 2009; 156: 250-261
92. Ikonomidis I, Parissis JT, Paraskevaidis I, Kourea K, Bistola V, Lekakis J, et al. Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure. Eur J Heart Fail 2007; 9: 1172-1177 (Pubitemid 350138499)
93. Boyd O, Grounds RM, Bennet ED. A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. JAMA 1993; 270: 2699-2707
94. Gan TJ, Soppitt A, Maroof M, el-Moalem H, Robertson KM, Moretti E, et al. Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery. Anesthesiology 2002; 97: 820-826
95. Kersten JR, Montgomery MW, Pagel PS, Warlitier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000; 90: 5-11 .
96. du Toit E, Hofmann D, McCarthy J, Pineda C. Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart 2001; 86: 81-87
97. Oldenburg O, Cohen MV, Yellon DM, Downey JM. Mitochondrial K(ATP) channels: role in cardioprotection. Cardiovasc Res 2002; 55: 429-437
98. Peart JN, Gross GJ. Sarcolemmal and mitochondrial K(ATP) channels and myocardial ischemic preconditioning. J Cell Mol Med 2002; 6: 453-464 (Pubitemid 44146430)
99. Gross GJ, Peart JN. KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 2003; 285: H921-H930. (Pubitemid 37048144)
100. Gross GJ, Fryer RM. Sarcolemmal versus mitochondrial ATPsensitive K+ channels and myocardial preconditioning. Circ Res 1999; 84: 973-979
101. Suzuki M, Sasaki N, Miki T, Sakamoto N, Ohmoto-Sekine Y, Tamagawa M, et al. Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest 2002; 109: 509-516 (Pubitemid 34171782)
102. Lascano EC, Negroni J A, del Valle HF. Ischemic shortening of action potential duration as a result of KATP channel opening attenuates myocardial stunning by reducing calcium influx. Mol Cell Biochem 2002; 236: 53-61.
103. Budas GR, Jovanovic S, Crawford RM, Jovanovic A. Hypoxia-induced preconditioning in adult stimulated cardiomyocytes is mediated by the opening and trafficking of sarcolemmal KATP channels. FASEB J 2004; 18: 1046-1048 (Pubitemid 39561520)
104. Carrasco AJ, Dzeja PP, Alekseev AE, Pucar D, Zingman LV, Abraham MR, et al. Adenylate kinase phosphotransfer communicates cellular energetic signals to ATP-sensitive potassium channels. Proc Natl Acad Sci USA 2001; 98: 7623-7628 (Pubitemid 32567998)
105. Crawford RM, Ranki HJ, Booting CH, Budas GR, Jovanovic A. Creatine kinase is physically associated with the cardiac ATP-sensitive K+ channel in vivo. FASEB J 2002; 16: 102-104
106. Kopustinskiene DM, Pollesello P, Saris NE: Levosimendan is a mitochondrial KATP channel opener. Eur J Pharmacol 2001; 428: 311-314 (Pubitemid 33016646)
107. Kopustinskiene DM, Pollesello P, Saris NE: Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 2004; 68: 807-812 (Pubitemid 39044509)
108. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N: Levosimendan, a novel Ca2 sensitizer, activates the glibenclamide-sensitive K channel in rat arterial myocytes. Eur J Pharmacol 1997; 333: 249-259 (Pubitemid 27387398)
109. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N: The novel calcium sensitizer levosimendan activates the ATP-sensitive K channel in rat ventricular cells. J Pharmacol Exp Ther 1997; 283: 375-383 (Pubitemid 27438984)
110. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol 2007, 50: 257-263 (Pubitemid 47428972)
111. Tritapepe L, De Santis V, Vitale D, Guarracino F, Pietropaoli P, Singer M. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graf surgery.Br J Anaesth 2009, 102: 198-204.